Suzanne D. Conzen, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and Chief of the Division of Hematology and Oncology. She specializes in the diagnosis and treatment of breast cancer.

Dr. Conzen earned her medical degree at Yale School of Medicine in New Haven, Connecticut, and completed her residency in internal medicine at New York Hospital-Cornell Medical Center in New York City. She then received advanced training in hematology and medical oncology through a clinical fellowship at Dartmouth-Hitchcock Medical Center and in molecular oncology through a research fellowship at Dartmouth Medical School in Bedford, New Hampshire. She also holds a master’s degree from the London School of Hygiene & Tropical Medicine.

Certified by the American Board of Internal Medicine in medical oncology, she joined the UT Southwestern faculty in 2019.

An established physician-scientist with multiple National Cancer Institute grants, Dr. Conzen focuses her lab’s research on the role of the glucocorticoid receptor in prostate, breast, and ovarian cancers. Her previous research at the University of Chicago led to the recognition of a role for glucocorticoid receptor signaling in breast cancer biology and, more recently, in cancer progression and therapy-resistance in prostate and ovarian cancer. Dr. Conzen also receives peer-reviewed funding from the Breast Cancer Research Foundation. She has published countless academic articles, contributed chapters to several books, and delivered scores of presentations.

Dr. Conzen is a member of the TBCRG endocrine resistance working group, and she previously served on the CALGB/Alliance breast committee. In addition, she has served as senior editor of Cancer Research and as Chair of the National Institutes of Health’s Cancer Etiology Study Section.

In 2006, she was elected to the American Society for Clinical Investigation.


Medical School
Yale University School of Medicine (1987)
New York Presbyterian Hospital, Cornell Campus (1990), Internal Medicine
Dartmouth-Hitchcock Medical Center (1995), Hematology Oncology
The University of Chicago (1998), Molecular Oncology


Featured Publications LegendFeatured Publications

Non-canonical dimerization of the androgen receptor and other nuclear receptors: implications for human disease.
Jiménez-Panizo A, Pérez P, Rojas AM, Fuentes-Prior P, Estébanez-Perpiñá E, Endocr Relat Cancer 2019 08 26 8 R479-R497
Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Tonsing-Carter E, Hernandez KM, Kim CR, Harkless RV, Oh A, Bowie KR, West-Szymanski DC, Betancourt-Ponce MA, Green BD, Lastra RR, Fleming GF, Chandarlapaty S, Conzen SD, Breast Cancer Res. 2019 07 21 1 82
Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling.
Ritch SJ, Brandhagen BN, Goyeneche AA, Telleria CM, BMC Cancer 2019 Apr 19 1 376
Magnetic Resonance Angiography Shows Increased Arterial Blood Supply Associated with Murine Mammary Cancer.
Mustafi D, Leinroth A, Fan X, Markiewicz E, Zamora M, Mueller J, Conzen SD, Karczmar GS, Int J Biomed Imaging 2019 2019 5987425
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Györffy B, Conzen SD, Clin. Cancer Res. 2018 Jul 24 14 3433-3446
Psychosocial Stress Exposure Disrupts Mammary Gland Development.
Johnson MB, Hoffmann JN, You HM, Lastra RR, Fernandez S, Strober JW, Allaw AB, Brady MJ, Conzen SD, McClintock MK, J Mammary Gland Biol Neoplasia 2018 06 23 1-2 59-73
Magnetic resonance spectroscopy detects differential lipid composition in mammary glands on low fat, high animal fat versus high fructose diets.
He D, Mustafi D, Fan X, Fernandez S, Markiewicz E, Zamora M, Mueller J, Sachleben JR, Brady MJ, Conzen SD, Karczmar GS, PLoS ONE 2018 13 1 e0190929
MRI reveals increased tumorigenesis following high fat feeding in a mouse model of triple-negative breast cancer.
Mustafi D, Fernandez S, Markiewicz E, Fan X, Zamora M, Mueller J, Brady MJ, Conzen SD, Karczmar GS, NMR Biomed 2017 Oct 30 10
Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.
Kach J, Long TM, Selman P, Tonsing-Carter EY, Bacalao MA, Lastra RR, de Wet L, Comiskey S, Gillard M, VanOpstall C, West DC, Chan WC, Griend DV, Conzen SD, Szmulewitz RZ, Mol. Cancer Ther. 2017 08 16 8 1680-1692
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF, Gynecol. Oncol. 2017 07 146 1 153-160